Recruiting Advanced Solid Tumors Studies in Melbourne
A Study of D3S 001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation
This is a first-in-human (FIH), multicenter, open-label, dose-escalation, and dose-expansion Phase 1/2 clinical trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and prel...
A Study of AZD3470, a PRMT5 Inhibitor, in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors
This is a first time in human (FTiH) Phase I/IIa, open-label, multi-centre study of AZD3470 in participants with advanced or metastatic solid tumors with MTAP deficiency. The study consists of several...
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
The purpose of this study is to assess the safety, tolerability, efficacy, pharmacokinetics (PK), and immunogenicity of AZD0901 as monotherapy and in combination with anti-cancer agents in participant...
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
Solid tumours are abnormal lumps of tissue that can occur in different parts of the body. The tumours involved in this study have specific genetic characteristics that can make them more aggressive an...
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
This is a Phase 1/2a, open-label, study to evaluate the safety and preliminary efficacy of intratumoral T3011 given alone and in combination with intravenous pembrolizumab in partients with advanced o...
A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)
This open-label, multicenter, rollover study will provide continued treatment for participants deriving benefit from different therapies received in studies sponsored by Daiichi Sankyo, Inc. (DS) or D...
About Advanced Solid Tumors Clinical Trials in Melbourne
Advanced solid tumors refer to cancers that have grown beyond the original site or spread to distant organs. Many clinical trials enroll patients with various types of advanced solid tumors to test novel therapies. These trials often investigate immunotherapy, targeted therapy, and combination approaches.
There are currently 6 advanced solid tumors clinical trials recruiting participants in Melbourne, VICTORIA. These studies are seeking a combined 1,053 participants. Research is being sponsored by D3 Bio (Wuxi) Co., Ltd, AstraZeneca, GlaxoSmithKline and 2 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Advanced Solid Tumors Clinical Trials in Melbourne — FAQ
Are there advanced solid tumors clinical trials in Melbourne?
Yes, there are 6 advanced solid tumors clinical trials currently recruiting in Melbourne, VICTORIA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Melbourne?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Melbourne research site will contact you about next steps.
Are clinical trials in Melbourne free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Melbourne studies also compensate for your time and travel.
What advanced solid tumors treatments are being tested?
The 6 active trials in Melbourne are testing new therapies including novel drugs, biologics, and treatment approaches for advanced solid tumors.
Data updated March 2, 2026 from ClinicalTrials.gov